It depends on the sector and then the company.
An appropriate amount of debt does lower the cost of capital and concentrates the equity rewards. If FMG has sustainably moved down the cost curve than 20-25% debt should be manageable, but concur than 10-15% would be about right given lack of diversification (commodity price risk and production chain risk).
Buying meaningful diversification though would mean big game hunting. At least a 5B market cap with existing strong cashflows. So either more debt or twiggy diluting. Neither sounds that palatable.
Some here though have confused what paying down the debt levels from here will mean, FMG equity passed the point of being discounted for debt stress some time back. The net debt is a straight deduction now from enterprise value, nothing more.
Agree completely on the buyback being the last priority. It is financially naive for some to have been clamouring for a buyback to precede an investment credit rating.
- Forums
- ASX - By Stock
- FMG
- Iron Ore Price
Iron Ore Price, page-18109
-
- There are more pages in this discussion • 1,949 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add FMG (ASX) to my watchlist
(20min delay)
|
|||||
Last
$22.53 |
Change
0.430(1.95%) |
Mkt cap ! $69.53B |
Open | High | Low | Value | Volume |
$22.41 | $22.64 | $22.22 | $63.86M | 2.839M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
20 | 7410 | $22.52 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$22.53 | 8 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
21 | 5860 | 22.530 |
23 | 9741 | 22.520 |
15 | 18422 | 22.510 |
15 | 9265 | 22.500 |
9 | 13573 | 22.490 |
Price($) | Vol. | No. |
---|---|---|
22.540 | 4526 | 16 |
22.550 | 8127 | 31 |
22.560 | 9470 | 15 |
22.570 | 5043 | 8 |
22.580 | 24077 | 12 |
Last trade - 15.26pm 15/07/2024 (20 minute delay) ? |
Featured News
FMG (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online